{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:16:01Z","timestamp":1779930961893,"version":"3.53.1"},"reference-count":81,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2017,4,29]],"date-time":"2017-04-29T00:00:00Z","timestamp":1493424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Despite its effectiveness, there are growing concerns regarding the risk of progressive multifocal leukoencephalopathy (PML), a brain infection caused by John Cunningham virus (JCV), particularly after 24 doses and in patients who previously received immunosuppressive drugs. Long-term natalizumab treated, immunosuppressive-pretreated, and JCV antibody-positive patients are asked to rediscuss natalizumab continuation or withdrawal after 24 doses. Until now, there has not been a clear strategy that should be followed to avoid PML risk and in parallel reduce clinical and radiological rebound activity. In this review, we analyzed the results of clinical trials and case reports in relation to the following situations: natalizumab continuation, natalizumab discontinuation followed by full therapeutic suspension or switch to other first or second line MS treatments. Quitting all MS treatment after natalizumab increases MS activity occurrence. The results regarding the therapeutic switch are not homogeneous, so at the moment there are no established guidelines regarding natalizumab treatment after 24 administrations; the choice is currently based on the professional experience of the neurologist, and on patients\u2019 clinical features and preferences.<\/jats:p>","DOI":"10.3390\/ijms18050940","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T11:37:20Z","timestamp":1493725040000},"page":"940","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Natalizumab in Multiple Sclerosis: Long-Term Management"],"prefix":"10.3390","volume":"18","author":[{"given":"Marinella","family":"Clerico","sequence":"first","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Artusi","sequence":"additional","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Liberto","sequence":"additional","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rolla","sequence":"additional","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bardina","sequence":"additional","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Barbero","sequence":"additional","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mercanti","sequence":"additional","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Durelli","sequence":"additional","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino, Orbassano (TO) 10043, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.24009","article-title":"Multiple sclerosis: Prospects and promise","volume":"74","author":"Hauser","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_2","unstructured":"(2017, February 16). MS Prevalence: National MS Society Study for New Prevalence Estimate. Available online: http:\/\/www.nationalmssociety.org\/About-the-Society\/MSPrevalence."},{"key":"ref_3","first-page":"S15","article-title":"Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis","volume":"19","author":"Tullman","year":"2013","journal-title":"Am. J. Manag. Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(94)91118-5","article-title":"Pathogenesis of multiple sclerosis","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.4049\/jimmunol.132.6.3011","article-title":"Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: Cell distribution and antigenic relation to components on resting cells and T cell lines","volume":"132","author":"Hemler","year":"1984","journal-title":"J. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0092-8674(90)90661-W","article-title":"VCAM-1 on activated endothelium inter-acts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4\/fibronectin binding site","volume":"60","author":"Elices","year":"1990","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1084\/jem.177.1.57","article-title":"Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma","volume":"177","author":"Baron","year":"1993","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1172\/JCI117519","article-title":"The pathophiologic role of alpha 4 integrins in vivo","volume":"94","author":"Lobb","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1242\/jcs.111.9.1165","article-title":"Osteopontin is a ligand for the \u03b14\u03b21 integrin","volume":"111","author":"Bayless","year":"1998","journal-title":"J. Cell Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.145.3.785","article-title":"Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules","volume":"145","author":"Davis","year":"1990","journal-title":"J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against \u03b14\u03b21 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Atlas","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis","volume":"353","author":"Tyler","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Sciot","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.12688\/f1000research.7513.2","article-title":"The TOUCH program and natalizumab: Fundamental flaw in patient protection","volume":"4","author":"Avasarala","year":"2016","journal-title":"F1000Research"},{"key":"ref_18","unstructured":"(2017, February 16). Number of PML Diseases under Tysabri. Available online: https:\/\/chefarztfrau.de\/?page_id=716."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/WCO.0b013e328360279f","article-title":"Progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"26","author":"Baldwin","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"Bertolotto","year":"2012","journal-title":"Mult. Scler. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1756285608101861","article-title":"Review: Natalizumab in the treatment of multiple sclerosis","volume":"2","author":"Yaldizli","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/344280","article-title":"Traffic of JC virus from sites of initial infection to the brain: The path to progressive multifocal leukoencephalopathy","volume":"186","author":"Sabath","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/infdis\/147.4.676","article-title":"Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues","volume":"147","author":"Chesters","year":"1983","journal-title":"J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/jvi.70.10.7004-7012.1996","article-title":"JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: Implications for viral latency","volume":"70","author":"Monaco","year":"1996","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/s-2008-1040837","article-title":"Progressive multifocal leukoencephalopathy","volume":"19","author":"Berger","year":"1999","journal-title":"Semin. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1017\/S0317167100028912","article-title":"Progressive multifocal leukoencephalopathy with gray matter involvement","volume":"16","author":"Ledoux","year":"1989","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_29","first-page":"191","article-title":"Progressive multifocal leukoencephalopathy: Its pathological features","volume":"105","author":"Richardson","year":"1983","journal-title":"Prog. Clin. Biol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1212\/01.WNL.0000081306.86961.33","article-title":"Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual","volume":"61","author":"Corey","year":"2003","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.21619","article-title":"Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons","volume":"65","author":"Dang","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: Consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2012-302478","article-title":"Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies","volume":"83","author":"Mentzer","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive Multifocal Leukeoncephalopathy Consortium. Progressive multifocal leukoencephalopathy: Current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1177\/1352458512467502","article-title":"The effect of plasma exchange on serum anti-JC virus antibodies","volume":"19","author":"Subramanyam","year":"2013","journal-title":"Mult. Scler. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_38","unstructured":"(2017, February 16). EMA Confirms Recommendations to Minimise Risk of Brain Infection PML with Tysabri. Availiable online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2016\/02\/WC500202389.pdf."},{"key":"ref_39","unstructured":"European Medicines Agency (2017, February 16). European Medicines Agency Recommends Additional Measures to Better Manage Risk of Progressive Multifocal Leukoencephalopathy (PML) with Tysabri. Available online: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/01\/news_detail_000987.jsp&mid=WC0b01ac058004d5c1."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0b013e31823c1200","article-title":"\u2018Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis\u2019: Author response","volume":"77","year":"2011","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ana.22083","article-title":"Considerations on discontinuing natalizumab for the treatment of multiple sclerosis","volume":"68","author":"Berger","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.msard.2014.04.003","article-title":"Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients","volume":"3","author":"Sangalli","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/ana.22074","article-title":"Natalizumab drug holiday in multiple sclerosis: Poorly tolerated","volume":"68","author":"Killestein","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"Marra","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"Goodman","year":"2011","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamaneurol.2014.1200","article-title":"Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study)","volume":"71","author":"Clerico","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers","volume":"4","author":"Capobianco","year":"2015","journal-title":"Neurol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1212\/NXI.0000000000000297","article-title":"Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort","volume":"3","author":"Papeix","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00415-016-8177-1","article-title":"Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients","volume":"263","author":"Iaffaldano","year":"2016","journal-title":"J. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2015-312221","article-title":"Randomised natalizumab discontinuation study: Taper protocol may prevent disease reactivation","volume":"87","author":"Hagemeier","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","author":"Vellinga","year":"2008","journal-title":"Neurology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis","volume":"138","author":"Iaffaldano","year":"2015","journal-title":"Brain"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000453333","article-title":"Observational Study of Switching from Natalizumab to Immunomodulatory Drugs","volume":"77","year":"2017","journal-title":"Eur. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Patti, F., Leone, C., and Zappia, M. (2015). Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: A case report. BMC Neurol., 15.","DOI":"10.1186\/s12883-015-0512-0"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10072-014-1960-9","article-title":"Recurrence of disease activity after repeated Natalizumab withdrawals","volume":"36","author":"Moiola","year":"2015","journal-title":"Neurol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Malucchi, S., Capobianco, M., Lo Re, M., Malentacchi, M., di Sapio, A., Matta, M., Sperli, F., and Bertolotto, A. (2016). High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: An Observational Study. Neurol. Ther.","DOI":"10.1007\/s40120-016-0058-0"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1468-1331.2011.03577.x","article-title":"Pulse monthly steroids during an elective interruption of natalizumab: A post-marketing study","volume":"19","author":"Borriello","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3109\/00207454.2015.1127919","article-title":"Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod","volume":"126","author":"Evangelopoulos","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/cns.12282","article-title":"Treatment options to reduce disease activity after natalizumab: Paradoxical effects of corticosteroids","volume":"20","author":"Rossi","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"513160","DOI":"10.1155\/2014\/513160","article-title":"Multiple sclerosis and pregnancy: Current considerations","volume":"2014","author":"Buraga","year":"2014","journal-title":"Sci. World J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/ane.12222","article-title":"Normal outcome of pregnancy with ongoing treatment with natalizumab","volume":"129","author":"Fagius","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/ane.12004","article-title":"Natalizumab treatment during pregnancy-effects on the neonatal immune system","volume":"127","author":"Schneider","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458514546790","article-title":"Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study","volume":"21","author":"Ebrahimi","year":"2015","journal-title":"Mult. Scler. J."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Friend, S., Richman, S., Bloomgren, G., Cristiano, L.M., Wenten, M., Alcalde-Cabero, E., Almaz\u00e1n-Isla, J., Garc\u00eda-Merino, A., S\u00e1, J., and Pedro-Cuesta, J. (2016). Evaluation of pregnancy outcomes from the Tysabri\u00ae (natalizumab) pregnancy exposure registry: A global, observational, follow-up study. BMC Neurol., 16.","DOI":"10.1186\/s12883-016-0674-4"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1352458516641775","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal","volume":"23","author":"Larochelle","year":"2017","journal-title":"Mult. Scler. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/1352458516640609","article-title":"Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?","volume":"23","author":"Haas","year":"2017","journal-title":"Mult. Scler. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clim.2017.01.001","article-title":"From natalizumab to fingolimod in eight weeks-Immunological, clinical, and radiological data in quest of the optimal switch","volume":"176","author":"Harrer","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study","volume":"83","author":"Goodman","year":"2014","journal-title":"Neurology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_76","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-010-0344-z","article-title":"Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: A post-marketing observational study","volume":"31","author":"Sangalli","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Misbah, S.A. (2017). Progressive multifocal leukoencephalopathy-driven from rarity to clinical mainstream by iatrogenic immunodeficiency. Clin. Exp. Immunol.","DOI":"10.1111\/cei.12948"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Oliveira, A.T., Lopes, S., Cipriano, M.A., and Sofia, C. (2015). Induced liver injury after high-dose methylprednisolone in a patient with multiple sclerosis. BMJ Case Rep., 2015.","DOI":"10.1136\/bcr-2015-210722"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182698c64","article-title":"Disease-Modifying drugs for multiple sclerosis in pregnancy; A systematic review","volume":"79","author":"Lu","year":"2012","journal-title":"Neurology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13023-015-0332-8","article-title":"Immunosuppressive drugs and fertility","volume":"10","author":"Leroy","year":"2015","journal-title":"Orphanet J. Rare Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/5\/940\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:34:13Z","timestamp":1760207653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/5\/940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,29]]},"references-count":81,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"alternative-id":["ijms18050940"],"URL":"https:\/\/doi.org\/10.3390\/ijms18050940","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,29]]}}}